Hospitals received a 20% Medicare add-on for COVID patients treated with Remdesivir, potentially generating close to $100 million per 5,000 patients. Meanwhile, the WHO, NIH, and EMA recommended against ivermectin despite early promising meta-analyses showing potential mortality reduction. Hospitals went to court to prevent patients from receiving ivermectin even with a doctor's prescription. The financial architecture of COVID treatment protocols raised serious questions about whether profit drove treatment decisions.